Vertex Pharmaceuticals Incorporated

NASDAQ:VRTX

Biotechnology

Healthcare
$536.45 -1.40%

-$6.43 today

Market cap
$136.01B
Beta
0.31
P/E (TTM)
26.5
EPS (TTM)
$17.07
52W Low $362.50High $507.92

Volume 1.29M

Average 1.26M

VRTX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Vertex Pharmaceuticals IncorporatedNASDAQ: VRTX

Research & Development · Q3 FY2026 · quarter ended Sep 2026

Research & development growth accelerates

Q3 FY2026 research & development of $1.32B rose 27.9% year over year, ahead of the +6.5% change in trailing-twelve-month research & development. Sequentially, it rose 32.9% from the prior quarter. Over 3 fiscal years it compounded at +12.2% a year.

Context

  • Research & development amounted to 31.1% of revenue in FY2025, down 1.9 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +27.9% holds above the trailing-twelve-month pace of +6.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$1.32B+32.9% QoQ
Last fiscal yearDec 2025
$3.75B+3.4% YoY
LTMSep 2026
$4.25B+6.5% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+27.9%——
1 year+3.4%——
3-year CAGR+12.2%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
3.75B USD
Year-over-year change
+3.4%
4-year CAGR
+5.3%

Research & Development vs competitors

How VRTX compares with its peers on the latest reported figures

  • VRTX's LTM Sep 2026 research & development of $4.25B is the 2nd highest of the 11 companies compared; the peer median is $650.95M.
  • Its year-over-year change of +6.5% is the 5th highest of 11, against a peer median of +3.9%.
  • Research & development amounts to 32.7% of revenue for VRTX, versus a peer median of 85.3%.
VRTX Competitors Peer median
Research & Development for VRTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$181.1B +19955.1%+12.4%17.6%
VRTXVertex Pharmaceuticals IncorporatedLTM Sep 2026$4.25B +6.5%+12.2%32.7%
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$1.51B +30.1%+14.5%31.4%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$923.16M +4.7%+3.2%96.2%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$902.58M -34.5%+20.2%41.3%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$770.95M +12.5%+2.0%115.2%
BBIOBridgeBio Pharma, Inc.LTM Jun 2026$530.96M +12.1%+6.1%74.5%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$433.31M -14.7%-11.3%43.0%
BEAMBeam Therapeutics Inc.LTM Jun 2026$408.66M +3.1%+9.5%261.9%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$361.17M -21.5%-2.5%546.5%
CRSPCRISPR Therapeutics AGLTM Sep 2026$283.28M +1.6%-16.9%1125.4%
Peer median (excluding VRTX) $650.95M+3.9%+4.7%85.3%

Competitors are the stored peer set for VRTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue7.57B8.93B9.87B11.02B12.07B
Cost of Revenue904.2M1.08B1.26B1.53B1.81B
Gross Profit6.67B7.85B8.61B9.49B10.27B
Gross Margin88.1%87.9%87.2%86.1%85.0%
Research & Development3.05B2.66B3.16B3.63B3.75B
Selling, General & Admin840.1M944.7M1.14B1.46B1.75B
Operating Expenses3.89B3.54B4.78B9.72B5.51B
Depreciation & Amortization125.6M148.3M181.3M207.2M209.8M
EBITDA2.92B4.44B4.61B486.3M4.87B
EBITDA Margin38.5%49.7%46.7%4.4%40.3%
Operating Income2.78B4.31B3.83B(232.9M)4.76B
Operating Margin36.7%48.2%38.8%-2.1%39.4%
Interest Income4.9M144.6M614.7M598.1M490.9M
Interest Expense61.5M54.8M44.1M30.6M13.3M
Other Income / Expenses(51.7M)(75M)547.8M481.4M(117.5M)
Income Before Tax2.73B4.23B4.38B248.5M4.64B
Pre-Tax Margin36.0%47.4%44.4%2.3%38.5%
Income Tax Expense388.3M910.4M760.2M784.1M690M
Net Income2.34B3.32B3.62B(535.6M)3.95B
Net Margin30.9%37.2%36.7%-4.9%32.7%
EPS (Basic)9.0912.9714.05(2.08)15.46
EPS (Diluted)9.0112.8213.89(2.08)15.32
Weighted Avg Shares257.7M256.1M257.7M257.5M255.7M
Weighted Avg Shares (Diluted)259.9M259.1M260.5M257.9M258M

Vertex Pharmaceuticals Incorporated

NASDAQ:VRTX

Intrinsic Alpha fair value

Locked

Current Price

$536.45

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.